Sana Q2 net loss $72.5M; cash runway extended into 2025 on manufacturing move savings

Sana Biotechnology, Inc.

2022-Q2 EPS reported -$0.56

Cash position $579.6M at June 30, 2022, down $167.3M from Dec 31, 2021.
Q2 net loss $72.5M ($0.39 per share) vs net income $18.7M in Q2 2021.
Expect cash runway into 2025; ~$100M cost savings from relocating manufacturing to Bothell, WA.
Plan to file INDs in 2022 for SC291 and SG295; SC451 (type 1 diabetes) IND in 2023.
Presented preclinical data showing survival of HIP pancreatic islet cells, cardiomyocytes, RPE cells in NHP.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.